Introduction {#sec1}
============

The SARS-CoV-2 virus that induces the pandemic of coronavirus disease 2019 (COVID-19) has infected more than 4 million people with over 320,000 casualties worldwide; the numbers are still increasing on a daily basis ([@bib104]). Currently, effective treatments or preventive SARS-CoV-2 vaccination are not available, although beneficial effects are observed by using respiratory ventilation or extracorporeal membrane oxygenation (ECMO) as life-supporting measures ([@bib67], [@bib48], [@bib81]). Potential antiviral agents including remdesivir and favipiravir are still under investigation ([@bib66], [@bib109]). Thus, although many infected people are able to self-recover or are cured with mild medication, inventing effective modalities or utilizing the existing therapies with proven safety to alleviate CS and ARDS remains as an urgent need ([@bib68]). The foremost life-threatening condition of ARDS is the highly elevated levels of cytokines and chemokines (termed the cytokine storm, CS) in the lungs caused by the heavy virus loading and the consequent overreaction of the host innate immune system. Thus, although a great effort is to be continued in pursuing of the anti-virus agents and vaccination ([@bib64], [@bib65]), new calls are made for inventing the host-directed approaches to block the virus-induced immune overreaction and CS in COVID-19 patients ([@bib71], [@bib116]). Therefore, the medications that can efficaciously prevent or reduce CS severity are to be urgently developed and/or tested.

Two major pathologic phases have been identified in the course of SARS-CoV-2-mediated lung dysfunction ([@bib24], [@bib110], [@bib112]). The initial phase illustrates the primary antiviral inflammatory response, at which stage enhancing the host immune activity to diminish virus loading is suggested to benefit the prognosis. In contrast, the advanced phase is characterized by the severely CS-induced endotoxic lung damages due to the immune overreaction with noticeable alveolar mucus accumulation and limitation of gas exchange capacity. At this stage, immune suppressive approaches are strongly recommended ([@bib54], [@bib67], [@bib98], [@bib108]). Thus, based on the radiation-mediated adaptive cell response ([@bib1]) and radiation-induced immune regulation ([@bib92]), as well as the histological data on pneumonia control by radiotherapy ([@bib21]), this perspective article is attempted to illustrate the potential effects of LR on CS in reducing ARDS in COVID-19 patients. The CS-preventive effects could be achieved by application of low-dose radiation (LDR) with the lung-safe dose range (equivalent to the dose received in a regular examination of computed tomography, CT). Without potential concern of major side effects, LDR could be repeated and precisely delivered to the infected area enhancing the anti-viral environment by rewiring epithelial cell metabolism and activating *in situ* immune cells. In addition, such a boosted host immune surveillance may also be beneficial in reducing the severity of CS due to LDR-mediated pre-consumption of immune reserves. On the another hand, when the symptoms of ARDS become obvious with the significant indications of CS in the lungs, a single dose of higher dose radiation (HDR) within the lung-tolerable dose range, could be an option for direct inhibition or elimination of the *in situ* overactive cytokine-releasing cells to suppress CS in the targeted local lung tissue. In addition, HDR to the CS tissue may restore a certain level of the alveolar gas exchange capacity via radiation-induced epithelial cell renewal and microvasculature modification. Because the radiation doses applied in LR will be in the lung-tolerable ranges, LR with LDR and HDR is proposed to serve as the alternative modalities to reduce ARDS in COVID-19 patients.

Pneumonia Radiotherapy {#sec1.1}
----------------------

Historically, LR and antiserum treatment were the only two choices for the control of bacteria- and virus-induced pneumonia. In fact, X-ray was used to treat pertussis/whooping cough from 1923 to 1936 in North America and Europe ([@bib22]). Surprisingly, LR was reported to reduce the pneumonia mortality to a similar rate as treated by immune serum and sulfonamide. In 2013, Calabreses and Dhawan published a milestone review on this historic period regarding control of different types of pneumonia by radiation ([@bib21]). Among a total of 863 pneumonia patients treated by X-ray therapy, including 85 virus-induced pneumonia and 36 interstitial pneumonia cases, the reported total cure rate was 83.1% (717 out of 863 cases), including 67 of 85 (78.8%) cases of virus-induced pneumonia and 22 of 29 (75.9%) cases of interstitial pneumonia ([@bib21]). In addition, animal model using feline-virus-induced cat pneumonia, which mimicked the human atypical pneumonia, showed that the incidence of pneumonia was reduced by 50% and 25%, respectively by radiation delivered 24 h and 48 h after the virus infection ([@bib11], [@bib33]). Impressively, the same group also demonstrated the survival advantage of LR in a mouse pneumonia model induced with high-risk swine influenza virus ([@bib11], [@bib33]). It is remarkable that the radiation-mediated pneumonia control was believed by then to be linked to the number and responsiveness of immune cells ([@bib41]). However, as noted by Calabrese and Dhawan, due to limitations, the control groups were not validated or well described in these studies, and little LR research has been conducted since 1946 ([@bib21]), which apparently is due to the emergence of more effective vaccines and antibiotics. Additional reasons are the well-documented radiation-associated complications such as lung fibrosis induced by thoracic irradiation (average dose range 45--65 Gy) ([@bib12], [@bib32]). Nevertheless, in the light of enormous scientific advances in the past century, especially in the fields of molecular biology, radiation biology, and immunology, and with the urgent situation of mitigating ARDS in COVID-19 patients, the potential benefits of LR should be reanalyzed. The latent LR therapeutic effects could be validated with the incredible advances in the methodologies that are able to precisely deliver the dose to the target tissue under sophisticated imaging-guided approaches. In addition, together with the modern biological technologies, more details of virus-induced pneumonia such as the virus genomic identification, virus loading, and cytokine increments can be quickly obtained in clinic. Thus, radiation-mediated host immune surveillance is worthy to be investigated in the control of CS with updated information of SARS-CoV-2, CS level, and the pathologic progression of ARDS. Radiation with LDR is well defined to induce an adaptive homeostatic function in mammalian cells, which fits into the need of boosting immune cells to reduce virus loading, whereas HDR may be considered to inhibit or eliminate the *in situ* overactive cytokine-generating immune cells to suppress CS.

Compared with the vanished LR, the antiserum modality of convalescent plasma used 100 years ago for pneumonia treatment remains as a modality in control of SARS-CoV-2. However, although clinical benefits have been reported in patients with SARS-CoV, H5N1, H1N1 influenza, Ebola virus, and MERS (Middle East Respiratory Syndrome), and recently SARS-CoV-2 ([@bib26], [@bib38], [@bib55], [@bib87], [@bib102], [@bib115]), convalescent plasma will face the same challenges of the mono-targeting of virus and the limited serum resource. LR does not have such weaknesses and holds the non-invasive advantage. With its broad impact on host cells, exceptional source availability, uncostly procedure, and adjustable doses, radiation is an ideal approach to regulate CS in prevention and/or mitigation of ARDS. The dose ranges applicable in LDR and HDR are to be carefully tested and optimized to precisely fit into the purpose of CS inhibition to minimize the risk of side effects. Based on the data from *in vitro* cell and *in vivo* animal experiments, and human data of radiation exposure, the dose range of LDR to a local lung area in the initial phase of virus infection is recommended as 0.1--0.5 Gy; and the range of HDR useful for eliminating *in situ* cytokine-generating cells is recommended as 3--8 Gy. Both dose ranges of radiation are tolerable by normal lung tissues and are below the clinical dosage used in clinic thoracic radiotherapy, thus minimizing the potential adverse effects.

LDR-Rewired Epithelial Cell Metabolism Limits Virus Replication {#sec1.2}
---------------------------------------------------------------

It is known that virus can hijack the metabolism in the host cells to meet the increased energy consumption for the fast virus replication. Both DNA and RNA viruses are able to reprogram the carbon metabolic pathways in the host cell by accelerating glycolysis and pentose phosphate activity to increase the energy demands for virus proliferation. Thaker et al. has demonstrated that viruses are depending on consuming the major nutrients including glucose and glutamine for anabolic augmentation ([@bib96]). Thus, LDR-enhanced mitochondrial-dominated oxygen metabolism in the lung epithelial cells will compete and/or inhibit such virus-mediated rewiring of bioenergetics to slow down virus replication and loading ([Figure 1](#fig1){ref-type="fig"}). LDR-induced biological homeosis in mammals has been extensively studied ([@bib72], [@bib76], [@bib105], [@bib19]). Such LDR-induced metabolism is demonstrated in an array of normal cells with increased ability of defending cells against genotoxic stress and cell transformation ([@bib6], [@bib14], [@bib15], [@bib18], [@bib20], [@bib43], [@bib72], [@bib80]). The LDR-mediated homeostasis is further identified with enhanced cellular capacity to detoxify damages of reactive oxygen species (ROS) by increasing mitochondrial antioxidant enzyme MnSOD and mitochondrial metabolic functions ([@bib23], [@bib35], [@bib45]). The adaptive cellular protection with enhanced metabolic function is linked with the large scale of genes upregulated by LDR, including the fundamental factors involved in DNA repair and pro-survival signaling pathways ([@bib13], [@bib56], [@bib90]), reduction of ROS ([@bib82], [@bib89]), as well as enhancing mitochondrial function and antioxidant activity ([@bib37]). Mice treated with whole-body LDR (10 cGy) were protective against radiation-induced cell death and inflammatory response ([@bib58]). Thus, application of LDR will help the host cells to reduce the rate of viral replication by a potential metabolic competition to deprive the virus energy dependence. In addition, LDR applied to the non-infected lung tissue may also be beneficial by increasing energy metabolism in the healthy cells to limit the scale of virus infection rate. However, the dose range for LDR in blocking virus loading in human lung epithelial cells is to be tested and optimized by tests with animal models.Figure 1LDR-Induced Metabolic Rewiring in Lung Epithelial and In Situ Immune Cells Enhances the Anti-Virus EnvironmentLDR-induced adaptive metabolic enhancement in lung epithalamium (including ciliated cells and alveolar type I and II cells) may limit virus replication via energy competition. In addition, LDR-enhanced mitochondrial function in the immune cells (e.g., T cell, B cell, macrophages) is able to increase the immune cell activity to release cytokines to attack virus. Thus, LDR-mediated epithelial metabolism and enhanced immune cell activity coordinatively increase the anti-virus environment in the infected lungs.

LDR-Activated *In Situ* Immune Cells Reinforce the Antiviral Condition {#sec1.3}
----------------------------------------------------------------------

Effective modalities capable of activating the *in situ* immune cell are urgently needed to reduce SARS-CoV-2-mediated CS. A weak immune force in the host tissue is well evidenced to cause CS via the increased viral loading in the lungs as well as in the circulation ([@bib68]). In addition to the protective function of LDR in lung epithelial cells, LDR-mediated immune activation has been observed by *in vitro* and *in vivo* models ([@bib5], [@bib100]). LDR-associated anti-inflammatory effects could be achieved by irradiation of either a locally infected area ([@bib4]) or the whole body ([@bib21], [@bib39]). Radiation-induced nitric oxide is shown to raise the function of macrophages ([@bib50]), and human lymphocytes pre-exposed to LDR exhibited an adaptive homeostasis, with reduced apoptosis and susceptibility to subsequent cytotoxic stress ([@bib29], [@bib76], [@bib86], [@bib105]). Additional human data demonstrated the LDR-induced adaptive activation in the lymphocytes isolated from the workers who received low levels of environmental or occupational radiation ([@bib9], [@bib43], [@bib69], [@bib93]). LDR-induced lymphocyte activation can enhance the local level of cytokines to enhance anti-viral force, thus reducing SARS-CoV-2 proliferation. Furthermore, it is shown that a constant immunogenic stimulation can cause lymphocyte exhaustion ([@bib117]). Thus, the immune cell activation by LDR before the onset of the CS may have a preventing effect to limit the coming wave of virus-induced CS. LDR may consume a critical portion of the "immune reserve," which is otherwise required to induce a full bursting of CS. Thus, in addition to LDR-induced metabolic advantage in lung epithelial cells described above, LDR-induced *in situ* immune cell activation and immune consumption may effectively reduce the CS severity and ARDS ([Figure 1](#fig1){ref-type="fig"}). The local anti-viral enhancement induced by LDR could be further increased via a potential radiation-induced immunogenicity in the infected lung tissue, which is described below.

Radiation-Mediated Immunogenicity Attracts Immune Cells to the Infected Area {#sec1.4}
----------------------------------------------------------------------------

Accumulating evidences indicate that radiation can increase the immune cell infiltration into a solid tumor via generation of immunogenic DNA and cellular damages. Such radiation-mediated immune priming effects have long been observed, termed as the "abscopal effect" due to radiation-induced tumor immunogenicity ([@bib17], [@bib42], [@bib78]). Radiation-induced damage-associated molecular patterns (DAMPs), including the high-mobility group box 1 protein (HMGB1), can enhance antigen presentation by dendritic cells (DCs) to T cells, thereby activating immune attack on irradiated tumor cells ([@bib8], [@bib40], [@bib52], [@bib31], [@bib113]). In addition, HMGB1 is shown to enhance the ability of immune cells to produce tumor necrosis factor α (TNF-α), interleukin 1 (IL-1), IL-6, and IL-8 ([@bib3]). Currently, it is unknown whether such radiation-associated immunogenicity in tumor cells could be strongly induced by radiation in normal human lung tissue. Importantly, it could be a study with high priority that LDR-induced lung tissue immunogenicity is a cross-priming of radiation-induced immunogenicity with a potential specific viral antigen. The first-needed supportive evidence could be an observation that circulating immune cells are significantly augmented into the irradiated areas as illustrated in [Figure 2](#fig2){ref-type="fig"}. The priming function of radiation was actually implicated in the early studies of virus-induced pneumonia in human and animal models ([@bib21]). The LDR-boosted recruitment of circulating immune cells will increase the immune cell presentation in the infected area to further block virus loading. Indeed, a single dose of 0.5 Gy was shown to cause the recruitment of NOS2-expressing macrophages and T cells into the irradiated area ([@bib59]). Stoecklein et al. have further demonstrated that a cluster of active immune cells, including macrophages, DCs, natural killer cells, T cells, and B cells, is dose-dependently activated in mice treated with whole-body irradiation with the dose range 1--4 Gy ([@bib92]). However, a remaining key question to be addressed is how effectively LDR can induce such immune priming function, which could be validated by experiments with soon available animal models generated with SARS-CoV-2-mediated CS and ARDS. Such *in vivo* tests may be able to identify a specific immunogenicity in the SARS-CoV-2-infected lungs that matches the potential immunogenicity in human lung tissue infected with SARS-CoV-2. It could be expected that the LDR-induced SARS-CoV-2 specific antigens efficaciously mobilize more host innate immune cells to the irradiated area. Thus, together with LDR-induced *in situ* immune cell activation, LDR-enhanced recruitment of circulating immune cells will further strengthen the antiviral environment.Figure 2LDR Potentially Induces a Radiation-Associated Cellular Immunogenicity in the Virus-Infected Lung Tissue Which Attracts Immune Cells to the Infected AreaRadiation-induced immunogenicity of tumor cells has been well demonstrated by enhanced immune cell infiltration into the solid tumors via radiation-enhanced antigen transfer by immune cells. It is thus assumed that LDR-treated lung tissue with virus infection may generate potential specific immunogenicity capable of attracting the circulating immune cells to the infected area to reduce the virus loading and the CS. The postulated specific antigens induced by different doses of radiation in the infected lung tissue are to be identified with the soon available animal models with the SARS-CoV-2-mediated ARDS.

Suppressing CS by HDR Elimination of *In Situ* Overactive Cytokine-Releasing Cells {#sec1.5}
----------------------------------------------------------------------------------

The lethal course of ARDS is related to the levels of CS-mediated lung dysfunction ([@bib68], [@bib114]). Contrasted to the need of activating immune cells to block virus loading for preventing CS, the major task during CS-medated ARDS is proposed to timely inhibit or eliminate the overactive cytokine/chemokine-releasing cells that include immune cells and the endothelial cells as demonstrated in [Figure 3](#fig3){ref-type="fig"}. The increased levels of cytokines and chemokines cause hyperinflammation, and the clinical symptoms of ARDS have been observed in the cases of ARDS induced by SARS-CoV-2 and other viruses including SARS, MERS, H1N1, and H5N1 ([@bib25], [@bib68], [@bib81], [@bib95]). At the onset of CS, the overreactive immune cells, including T cells, B cells, macrophages, natural killer cells, DCs are mobilized to infected areas. These overactive immune cells together with the endothelial cells ([@bib94]) are the major cells releasing cytokines and chemokines, including IL-2, IL-7, granulocyte colony-stimulating factor (GCSF), interferon-γ-inducible protein 10 (IP-10, CXCL10), monocyte chemoattractant protein 1 (MCP-1, CCL2), macrophage inflammatory protein 1-α (MIP-1α), TNF-α, and ferritin. A cluster of 14 cytokines has been specified in COVID-19 patients, and three of them, CXCL10, CCL7, and the IL-1 receptor antagonist, have been linked with the poor prognosis of COVID-19 due to increased virus loading and lung dysfunction ([@bib103], [@bib111]). Thus, effective inhibition of the overactive cytokine-releasing cells in the CS tissue is required to reduce the severity of CS and ARDS. However, the doses of HDR that can instantly eliminate the *in situ* cytokine-generating cells for suppressing CS with minimal adverse effect is to be determined.Figure 3Eliminating the In Situ Overactive Cytokine-Releasing Immune Cells by HDR to Reduce the Severity of CSHDR-mediated immune suppression via the direct cytotoxicity on active immune cells may serve as an applicable tool in eliminating the local *in situ* overactive cytokine-releasing cells to reduce CS. Due to a relatively high radiosensitivity of lymphocytes, HDR may effectively suppress the cytokine-releasing immune cells and endothelial cells in the infected lung tissue. Thus, a treatment with HDR within the lung tolerable radiation doses may serve as a choice to instantly suppress CS for relieving the severity of ARDS by removing the cytokine-releasing cells.

HDR-mediated immune suppression has long been applied to the treatments of many human diseases, including patients receiving bone marrow transplantation. Due to the feature of multiple cytokines involved in the CS, blocking or inhibiting a limited number of cytokines may be insufficient to suppress the CS or ARDS ([@bib25], [@bib63], [@bib107]). In addition, endothelial cells in the lungs have a similar radiosensitivity with immune cells ([@bib49]) and are also actively involved in influenza-induced cytokine generation and the CS ([@bib94]). Therefore, it is reasonable to assume that LR with HDR is able to at least temporally suppress CS by targeting the cytokine-generating immune cells and endothelial cells ([@bib28], [@bib60], [@bib95]). Because lung epithelial cells are relatively resistant to radiation, the lung epithelial cells may be relatively less damaged by HDR, thus remaining a potential ability in restoring alveolar gas exchange under CS-inhibited condition. This suggestion is encouraged by the facts that human lymphocytes are known to belong to the most radiosensitive mammalian cells ([@bib53], [@bib88], [@bib101]). A single dose of 1.5-Gy radiation can kill 50% of lymphocytes in the lymph nodes ([@bib101]), and their nuclear degradation occurred as early as 1 h post-irradiation ([@bib83], [@bib84], [@bib101]). Such interphase cell death is mainly mediated via p53-dependent apoptosis ([@bib2], [@bib85]), although some activated lymphocytes, such as CD4^+^ regulatory T cells and antigen-experienced and memory T cells, are shown to be slightly radioresistant compared with naive T cells ([@bib16], [@bib34], [@bib44], [@bib79]). In contrast, CD8+ T cells are the most radiosensitive lymphocyte population ([@bib30], [@bib106]). Data from Fornace lab have further identified that radiation with 3 Gy can effectively block T cell activation by impairing metabolic pathways ([@bib62]). Therefore, based on above radiobiologic evidences, the goal of CS inhibition by HDR may be achievable by application of a dose in the HDR range 3--8 Gy that is still below the standard total dosage of thoracic radiotherapy ([@bib36]). Such potential HDR benefits could be enhanced by precisely targeting radiation with imaging guidance to the CS area or a lobe in the infected lungs enriched with images of CS. However, unquestionably, the HDR-mediated CS suppression will be carefully tested and evaluated with the details of basal health conditions including overall lung function, severity of CS, as well as serum levels of cytokines.

Improving Alveolar Gas Exchange by HDR-Induced Vasculature Modification {#sec1.6}
-----------------------------------------------------------------------

It has been well documented that HDR induces reoxygenation in the hypoxic area in the poor-circulated solid tumor ([@bib51], [@bib70], [@bib75]). The respiratory system in humans is co-developed with the cardiovascular system via crosstalk and integration of multiple cellular populations ([@bib73]). Adult human lungs have functional gas exchange surfaces of about 70 m^2^ with a tremendous compensation ability ([@bib10]). Under conditions of repairing cellular loss or lung function deficiency, the alveolar cells are able to self-renew and proliferate to restore normal alveolar structure and gas exchange function, which are regulated via an integrated network of mesenchymal, endothelial, and epithelial cells and other components ([@bib7], [@bib61]). The direct lethal course of SARS-CoV-2 is due to the severely damaged alveolar gas exchange resulted from CS, leading to lower blood oxygenation ([@bib27], [@bib47]). The associated major pathologic alterations related to the reduced gas exchange capacity are identified as proteinaceous exudate with globules, epithelial cell proliferation with inflammatory cell infiltration, formation of multinucleated giant cells, and hyaline membrane formation in the alveolus ([@bib99]). Such pathological features in the lungs of COVID-19 patients are also found to be shared with other virus-induced pneumonia.

The defective circulation induced by CS makes it difficult to rescue the dysfunctional lung tissue in COVID-19 patients. The drainage of mucus from the alveoli under CS is more challenging due to inflammation-mediated congestion, which further worsens the circulation and mucus accumulation, damaging the gas exchanging efficacy. Such a "locked area" may severely limit the access by medications using drugs and/or antiviral agents. As postulated by the scheme shown in [Figure 4](#fig4){ref-type="fig"}, HDR-mediated modifications in the microvasculature in the poor-circulated CS tissue may help to improve the absorption of alveolar mucus due to HDR-induced cell apoptosis and the potential modification of microvasculature via endothelial cell renewal. Thus, the proposed HDR-mediated effects in alveolar clearance may be achievable based on the relative radiosensitivity of endothelial cells that are radiosensitive epithelial cells. Teijaro et al. have revealed that blocking S1P(1) receptor that is expressed on both endothelial cells and lymphocytes in the lung can suppress CS with reduced mortality in mice infected with human influenza virus ([@bib94]). In addition, the lung microvasculature is shown to contain heterogenic endothelial subpopulations with various vasculogenic capacities coordinately contributing to lung injury response ([@bib74], [@bib91]). Notably, proliferation of the lung endothelial cell subpopulation is enhanced during influenza-mediated lung injury ([@bib10], [@bib74]). On the other hand, cutaneous low-dose radiation has been shown to increase tissue vascularity through upregulation of angiogenic and vasculogenic pathways ([@bib97]). Thus, an optimized stimulus by a proper radiation dose of HDR to the CS tissue may effectively improve the local circulation and alveolar gas exchange function. However, this point of view on HDR-mediated alveolar mucus absorption is to be debated and needs to be further evaluated and approved by experimental data. It is assumed that although HDR-induced adverse effects such as lung fibrosis is a potential concern, the weighting on LR potential function could be favored to the urgent need of restoring the alveolar function to at least temporally relieving the severe situation of the acute respiratory failure in ARDS.Figure 4Potential Alveolar Mucus Absorption by Radiation-Induced Vascular ModificationThe major lethal course in COVID-19 patients is associated with the dropped blood oxygenation level due to CS-induced damages in alveoli gas exchange capacity. The drainage of alveolar mucus in the inflammation-mediated congestion has been a challenge in the treatment of COVID-19 patients due to limited access of medications using blood-delivered drugs and/or antiviral agents. Radiation has the potential ability of tissue re-oxygenation by medication of microvasculature in the hypoxic area in solid tumor. Thus, with the unique capacity of deep tissue penetration, LR of HDR may be able to improve gas exchange capacity by effectively relieving the alveolar mucus accumulation via radiation-mediated microvasculature alternations that includes endothelial cell apoptosis and replace. The potential benefits and effectiveness of HDR-accelerated mucus clearance are to be tested by animal models.

Perspectives {#sec2}
============

Further research on LR-mediated potential therapeutic benefits is urgently needed for enhancing the control of the CS and ARDS in COVID-19 patients. Based on the pathological progression, early lung injuries are caused by direct virus-induced cytopathic changes, followed by an advanced phase of CS-induced massive lung injury and ARDS. Thus, a potential effective window time for RL should be validated by monitoring the progress of virus infection including blood cytokine levels, lung CT images, and clinical symptoms. For the purpose of preventing CS by LDR, animal tests are to be conducted to determine the effects of LDR in treatments of both infected and uninfected lung areas for enhancing the immune surveillance in blocking or reducing virus loading. Data from animal studies have showed that LDR treatment 24 h after virus infection reduced the duration of the acute inflammatory phase from 10 days to 5 days ([@bib4], [@bib21]). Accordingly, LDR in the very low-dose range (e.g., 0.1--0.5 Gy) could be safely repeated to the infected lung areas within 24--72 h after the appearance of virus-inducted inflammatory response. Instead, for instant elimination of the overactive cytokine-releasing cells by HDR, both *in vitro* and *in vivo* models are to be applied to ascertain whether a dose of 2 Gy or above to the local area or a lobe with significant CS could effectively inhibit cytokine levels. In addition, improved quality of radiation sources, such as high-energy particles, has been shown to induce tumor immunogenicity ([@bib46], [@bib57], [@bib77]), which is also worthy to be investigated for enhancing the potential effects of LR with LDR and HDR. The potential HDR-induced side effects could be further reduced by application of such high-energy radiation sources within the standard range of lung tolerable doses as set by the European Organization for Research and Treatment of Cancer (EORTC).

Conclusions {#sec2.1}
-----------

This perspective is attempted to reevaluate a potential benefit of lung radiotherapy with varied radiation doses to fit into the needs of CS control at different stages of SARS-CoV-2 infection. To prevent CS, LDR is suggested to apply in the phase of virus infection to reduce virus loading, whereas HDR could be a choice to instantly eliminate the overactive cytokine-releasing cells to suppress CS thus relieving ARDS. It is expected that with the soon available animal models of SARS-CoV-2-induced pneumonia, the timing and dosage of LDR and HDR could be investigated and more precisely validated. Meanwhile, clinical trials could be conducted with LDR that is relatively safe by application of local radiation via a careful selection of patients with confirmed phase of viral loading. Most importantly, the proposed LR may be considered to synergize the effects of antiviral and life-supportive modalities to improve lung functions in COVID-19 patients. LDR may especially enhance the effectiveness of drugs that can reduce the production of mucus by alveolar cells. Nevertheless, in order to efficaciously reduce the onset and duration of the CS without severe lung adverse effects, LR needs to be precisely evaluated on its potential effects in control of CS and ARDS. All of these tasks and potential clinical benefits may only be achieved by overcoming the challenges in experimental models and via pre-clinical trials. Regardless, it is hoped that LR may shed light on the way out of the current darkness.
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